Scientists track how language fades in rare brain disease

NCT ID NCT00537004

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 500 people with primary progressive aphasia, a condition that slowly damages the brain's language areas. Researchers will use brain scans and language tests to map how the disease progresses over time. The goal is to better understand the disease, not to test a treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could help doctors better predict how language and brain changes progress in primary progressive aphasia, potentially guiding future care.

What could go wrong

This is an observational study, not a treatment trial. It will not provide a cure or therapy, and results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY PROGRESSIVE APHASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aphasia frontotemporal dementia Frontotemporal Lobar Degeneration primary progressive aphasia progressive non-fluent aphasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60611, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••